Index - P/E - EPS (ttm) -3.28 Insider Own 72.19% Shs Outstand 34.67M Perf Week 11.48%
Market Cap 81.76M Forward P/E - EPS next Y -1.40 Insider Trans -0.07% Shs Float 16.72M Perf Month 8.80%
Enterprise Value -26.39M PEG - EPS next Q -0.23 Inst Own 21.93% Short Float 4.31% Perf Quarter 10.57%
Income -198.87M P/S 30.51 EPS this Y 49.04% Inst Trans -39.95% Short Ratio 1.56 Perf Half Y -77.52%
Sales 2.68M P/B 117.04 EPS next Y 15.18% ROA -68.22% Short Interest 0.72M Perf YTD -77.74%
Book/sh 0.01 P/C 0.54 EPS next 5Y 20.64% ROE -245.59% 52W High 22.50 -93.96% Perf Year -79.97%
Cash/sh 2.53 P/FCF - EPS past 3/5Y 13.12% 7.57% ROIC -528.32% 52W Low 0.92 47.83% Perf 3Y -92.67%
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin -243.45% Volatility 7.06% 6.21% Perf 5Y -98.03%
Dividend TTM - EV/Sales -9.85 EPS Y/Y TTM 23.82% Oper. Margin -6398.81% ATR (14) 0.09 Perf 10Y -
Dividend Ex-Date - Quick Ratio 5.71 Sales Y/Y TTM 27.36% Profit Margin -7417.79% RSI (14) 60.88 Recom 3.00
Dividend Gr. 3/5Y - - Current Ratio 5.71 EPS Q/Q -4.36% SMA20 10.66% Beta 0.57 Target Price 1.12
Payout - Debt/Eq 62.80 Sales Q/Q 0.40% SMA50 9.74% Rel Volume 1.14 Prev Close 1.32
Employees 149 LT Debt/Eq 52.77 Earnings May 08 SMA200 -76.01% Avg Volume 461.47K Price 1.36
IPO Sep 18, 2019 Option/Short Yes / Yes EPS/Sales Surpr. -116.33% -88.25% Trades
Volume 526,792 Change 3.03%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-10-25 Downgrade Stifel
Buy → Hold
$27 → $2.50
Jan-10-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$20 → $1.50
Jan-10-25 Downgrade Morgan Stanley
Equal-Weight → Underweight
$12 → $2
Jan-10-25 Downgrade Guggenheim
Buy → Neutral
Jan-10-25 Downgrade BMO Capital Markets
Outperform → Market Perform
$21 → $2
Dec-06-24 Initiated BMO Capital Markets
Outperform
$21
Oct-01-24 Downgrade Truist
Buy → Hold
$24 → $12
Oct-01-24 Downgrade JP Morgan
Neutral → Underweight
$12 → $9
Feb-09-24 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed Jefferies
Buy
$61 → $55
Oct-17-22 Initiated JP Morgan
Neutral
$27
Aug-29-22 Initiated BofA Securities
Buy
$34
Dec-13-21 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade Wedbush
Neutral → Outperform
Aug-26-21 Initiated Morgan Stanley
Overweight
$100
Jan-29-21 Initiated RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade Wedbush
Outperform → Neutral
Show Previous Ratings
Jul-01-25 08:58AM
Jun-12-25 09:20AM
May-13-25 05:45PM
May-12-25 05:40PM
May-08-25 08:25AM
10:00AM
Loading…
Feb-27-25 10:00AM
Feb-05-25 09:35AM
Jan-11-25 10:55AM
Jan-10-25 12:43PM
07:55AM
06:43AM
Jan-09-25 01:00PM
10:00AM
Nov-08-24 08:00AM
07:00AM
07:00AM
Loading…
Nov-04-24 07:00AM
Oct-01-24 05:09PM
04:03PM
(Investor's Business Daily)
02:39PM
11:40AM
09:52AM
08:00AM
Sep-30-24 04:01PM
Sep-18-24 09:33AM
Sep-10-24 04:05PM
Aug-22-24 12:00PM
Aug-14-24 08:00AM
07:00AM
Jul-12-24 09:35AM
May-29-24 07:00AM
02:38PM
Loading…
May-10-24 02:38PM
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM
04:10PM
May-07-24 07:00AM
May-03-24 10:00AM
Apr-30-24 12:00PM
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
(GlobeNewswire) -7.06%
-10.66%
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
(GlobeNewswire) +5.92%
-22.13%
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Weber Steven PRINCIPAL ACCOUNTING OFFICER Jun 16 '25 Sale 1.20 486 583 26,530 Jun 20 08:24 PM Tahir Misbah CHIEF FINANCIAL OFFICER Jun 16 '25 Sale 1.20 1,522 1,825 178,802 Jun 20 08:23 PM Harler Mary Beth Chief Executive Officer Jun 16 '25 Sale 1.20 1,522 1,825 338,181 Jun 20 08:20 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Jun 16 '25 Sale 1.20 951 1,140 72,578 Jun 20 08:19 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER May 14 '25 Sale 1.12 1,865 2,090 27,016 May 16 04:05 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '25 Sale 1.23 1,701 2,092 28,881 Mar 18 07:10 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '25 Sale 1.23 7,329 9,015 180,324 Mar 18 07:09 PM Harler Mary Beth Chief Executive Officer Mar 14 '25 Sale 1.23 7,329 9,015 339,703 Mar 18 07:08 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '25 Sale 1.23 4,512 5,550 73,529 Mar 18 07:07 PM Misbah Tahir Officer Mar 14 '25 Proposed Sale 1.29 8,259 10,654 Mar 14 07:17 PM Mary Beth Harler Officer Mar 14 '25 Proposed Sale 1.29 8,259 10,654 Mar 14 07:16 PM Lisa Lynn Decker Officer Mar 14 '25 Proposed Sale 1.29 5,079 6,552 Mar 14 07:14 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Jan 15 '25 Sale 1.70 1,122 1,907 30,582 Jan 17 05:54 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Dec 16 '24 Sale 7.48 539 4,032 31,704 Dec 18 07:12 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Dec 16 '24 Sale 7.48 1,063 7,951 78,041 Dec 18 07:11 PM Harler Mary Beth Chief Executive Officer Dec 16 '24 Sale 7.48 1,708 12,776 347,032 Dec 18 07:11 PM Tahir Misbah CHIEF FINANCIAL OFFICER Dec 16 '24 Sale 7.48 1,708 12,776 187,653 Dec 18 07:10 PM Fred Schwarzer Former Officer and Director Dec 16 '24 Proposed Sale 7.17 32,250 231,232 Dec 16 05:36 PM Bruce Keyt Former Officer Dec 16 '24 Proposed Sale 7.17 18,762 134,524 Dec 16 05:34 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Sep 13 '24 Sale 11.54 469 5,412 25,543 Sep 17 08:58 PM Takimoto Chris H CHIEF MEDICAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 154,331 Sep 17 08:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 122,694 Sep 17 08:54 PM Schwarzer Fred CEO AND PRESIDENT Sep 13 '24 Sale 11.54 3,946 45,532 250,124 Sep 17 08:52 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 242,948 Sep 17 08:50 PM Harler Mary Beth Head, Research & Autoimmunity Sep 13 '24 Sale 11.54 1,487 17,158 163,740 Sep 17 08:44 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Sep 13 '24 Sale 11.54 925 10,673 79,104 Sep 17 08:42 PM Hambleton Julie Director Jul 25 '24 Option Exercise 1.39 15,132 21,033 17,132 Jul 29 05:45 PM Hambleton Julie Director Jul 25 '24 Sale 14.00 15,132 211,848 2,000 Jul 29 05:45 PM
